PROGNOSTIC FACTORS OF POSITIVE RESULTS OF MULTIFOCAL TRUS-GUIDED VESICOURETHRAL ANASTOMOSIS BIOPSY IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY

Purpose. To evaluate influence of clinical, biochemical and histological factors to detection rate of local recurrence following radical prostatectomy (RPE) using multifocal TRUS-guided vesicourethral anastomosis (VUA) biopsy.

Material and methods. 59 patients with newly diagnosed biochemical recurrence (BR) after RPE were included into prospective study. All of them underwent multifocal TRUS-guided VUA biopsy. Сlinical variables (serum prostate-specifi c antigen [PSA] level and PSA kinetics, time RPE-BR, Gleason grade, stage after RPE and clinical findings) were evaluated. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed.

Results. The detection rate of local prostate recurrence with TRUS-guided VUA biopsy was 45,8 % (95 % CI 33,7–58,3). At multivariate analysis only PSA level at the moment of biopsy (≤ 1,5 ng/ml vs > 1,5 ng/ml) and time RPE-BR (≤ 15 months vs > 15 months) were significantly associated with positive results of multifocal TRUS-guided VUA biopsy (p < 0,05).

Conclusion The detection rate of local prostate recurrence with TRUS-guided VUA biopsy depends on combination of independent predictors (PSA level at the moment of biopsy and time RPE—BR).

1. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines of prostate cancer. Eur Urol 2008;53:68–80.

2. Laufer M., Pound C.R., Carducci M.A. et al. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 2000; 55: 309–15.

3. Partin A.W., Oesterling J.E. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358–68.

4. Han M., Partin A.W., Zahurak M.et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169:517–23.

5. Алгоритмы диагностики и лечения злокачественных новообразований. Под ред. И.В. Залуцкого, Э.А. Жаврида. Минск, 2007; с. 351−72.

6. Zincke H., Osterling J.E., Blute M.L. et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152:1850–7.

7. Leventis A.K., Shariat S.F., Slawin K.M. Local recurrence after radical prostatectomy. Correlation of US features with prostatic fossa biopsy findings. Radiology 2001; 219: 432–9.

8. Scattoni V., Roscigno M., Raber M. et al. Biopsy of the vesico-urethral anastomosis after radical prostatectomy: when and how. Eur Urol 2002;38 (Suppl 1):89–95.

9. Goldenberg S.L., Carter M., Dashefsky S., Cooperberg P.L. Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol 1992;147:1307–9.

10. Parra R.O, Wolf R.M., Huben R.P. The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation. J Urol 1990;144:707–9.

11. Lightner D.J., Lange P.H., Reddy P.K., Moore L. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 1990;144:921–6.

12. Abi-Aad A.S., Macfarlane M.T., Stein A., DeKernion J.B. Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 1992;147:952–5.

13. Connolly J.A., Shinohara K., Presti J.C. Jr., Carroll P.R. Local recurrence after radical prostatectomy. characteristics in size, location, and relationship to prostatespecific antigen and surgical margins. Urology 1996;47:225–31.

14. Crook J., Robertson S., Collin G. et al. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993;27:31–7.

15. Scattoni V., Montorsi F., Picchio M. et al. Diagnosis of local recurrence after radical prostatectomy. B J U International 2004; 93:680–8.

16. Kahn D., Williams R.D., Manyak M.J. et al. 111Indium capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer afterradical prostatectomy. The ProstScint Study Group. J Urol 1998;159(6):2041–6.

17. Raj G.V., Partin A.W., Polascik T.J. Clinical utility of Indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002;94(4):987–96.

18. Shekarriz B., Upadhyay J., Wood D.P. Jr. et al. Vesicourethral anastomosis biopsy after radical prostatectomy. Predictive value of prostate-specific antigen and pathologic stage. Urology 1999;54:1044–8.

19. Scattoni V., Roscigno M., Raber M. et al. Multiple vesico-urethral biopsies following a radical prostatectomy. The predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003; 44:407–14.

20. Saleem M.D., Sanders H., Abu El Naser M., El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998;51:283–6.

21. Jhaveri F., Klein E. How to explore the patients with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin Urol Oncol 1999;17:130–4.

22. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632–42.

23. Neulander E.Z., Soloway M.S. Failure after radical prostatectomy. Urology 2003;61:30–6.

24. Partin A.W., Pearson J.D., Landis P.K. et al. Evaluation of prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence versus distant metastases. Urology 1994;43:649–59.

25. Patel A., Dorey F., Franklin J., DeKernion J.B. Recurrence pattern after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158:1441–5.